via Vaxart is a clinical stage biopharmaceutical company that seems to hold a great deal of promise. They are developing several oral tablet vaccines with the most promising being a vaccine for seasonal influenza. As noted on the company's website, the global vaccine market is worth $30 billion and a room temperature stable tablet has the potential to be a game changer. article source
